問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Otolaryngology

Division of General Internal Medicine

Division of Hematology & Oncology

Division of General Surgery

Division of Colorectal Surgery

Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

National Taiwan University Hospital

更新時間：2023-09-19

邱泰然Chiu, Tai-Jan
  • Principal Investigator
  • Clinical Trial Experience (year) 13 years 2 個月

  • kuerten@cgmh.org.tw

Recruiting Trial

116Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

邱泰然

List

220Cases

2012-11-30 - 2017-06-30

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2021-07-01 - 2022-08-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting2Sites

Terminated1Sites

2016-06-07 - 2020-03-31

Phase II

A Phase 2a Study to evaluate the clinical efficacy of JNJ-42756493(erdafitinib), a pan-Fibroblast Growth Factor Receptor (FGFR) tyrosine kinase inhibitor, in Asian patients with advanced non-small-cell lung cancer, urothelial cancer, esophageal cancer, or cholangiocarcinoma.

  • Condition/Disease

    advanced non-small-cell lung cancer, urothelial cancer, esophageal cancer, or cholangiocarcinoma

  • Test Drug

    JNJ-42756493

Participate Sites
6Sites

Not yet recruiting1Sites

Terminated4Sites

Study ended1Sites

2015-10-22 - 2019-12-31

Phase III

A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients

  • Condition/Disease

    Squamous Cell Head and Neck Cancer

  • Test Drug

    MEDI4736; Tremelimumab

Participate Sites
8Sites

Terminated7Sites

謝清昀
China Medical University Hospital-Taipei

未分科

楊慕華
Taipei Veterans General Hospital

Division of Otolaryngology

2014-06-01 - 2017-12-31

Phase III

A randomized, double-blinded, placebo controlled, multicentre phase III study to assess the efficacy and safety of olaparib (AZD2281) in combination with paclitaxel, compared to placebo in combination with paclitaxel, in Asian patients with advanced gastric cancer (including the gastro-oesophageal junction) who have progressed following first line therapy

  • Condition/Disease

    advanced gastric cancer

  • Test Drug

    Olaparib

Participate Sites
5Sites

Terminated5Sites

2020-05-12 - 2023-12-31

Phase III

A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor

  • Condition/Disease

    Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

  • Test Drug

    Monalizumab Cetuximab(ErbituxR)

Participate Sites
9Sites

Recruiting9Sites

謝清昀
China Medical University Hospital

2020-01-01 - 2024-12-31

Phase I/II

Phase 1b/2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-HER2 Bispecific Antibody ZW25 in Combination With Chemotherapy With/Without Tislelizumab in Patients With Advanced HER2-positive Breast Cancer or Gastric/Gastroesophageal Junction Adenocarcinoma

  • Condition/Disease

    Breast Cancer or Gastric/Gastroesophageal Junction Adenocarcinoma

  • Test Drug

    ZW25; Tislelizumab (BGB-A317)

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2020-08-01 - 2025-07-01

Phase I

A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-579 Alone and in Combination With Anti-PD-1 in Subjects With Locally Advanced or Metastatic Tumors

  • Condition/Disease

    Locally Advanced or Metastatic Tumors

  • Test Drug

    ABBV-CLS-579

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

2023-12-01 - 2027-03-31

Phase II

A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination With Fluorouracil, Folinic Acid, and Bevacizumab in Previously Treated Subjects With Unresectable Metastatic Colorectal Cancer

  • Condition/Disease

    Unresectable Metastatic Colorectal Cancer

  • Test Drug

    ABBV-400

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting3Sites

2014-07-01 - 2020-12-31

Phase III

A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma Patients

  • Condition/Disease

    Advanced Nasopharyngeal Carcinoma

  • Test Drug

    Epstein-Barr virus-specific autologous cytotoxic T lymphocytes

Participate Sites
8Sites

Terminated7Sites

王宏銘
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

謝清昀
China Medical University Hospital-Taipei

未分科

1 13 14 15 16 17 22
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB